Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Medium- to Long-Term Impact of Rotavirus Vaccination on Hospital Care in Belgium: A 7-Year Follow-Up of the Rotavirus Belgium Impact Study (RotaBIS).

Standaert B, Strens D, Alwan A, Raes M.

Infect Dis Ther. 2016 Mar;5(1):31-44. doi: 10.1007/s40121-015-0099-1. Epub 2015 Dec 31.

2.

Full Economic Assessment of Rotavirus Vaccination Using the Health Economic Cauliflower Toolbox.

Schecroun N, Li X, Standaert B.

Value Health. 2015 Nov;18(7):A729. doi: 10.1016/j.jval.2015.09.2780. Epub 2015 Oct 20. No abstract available.

PMID:
26534085
3.

The Vaccine Portfolio Management Model as an Efficiency Tool for Japan.

Schecroun N, Van Vlaenderen I, Morioka Y, Topachevskyi O, Standaert B.

Value Health. 2015 Nov;18(7):A728. doi: 10.1016/j.jval.2015.09.2771. Epub 2015 Oct 20. No abstract available.

PMID:
26534076
4.

Cost Analysis of Two Methods for Improving the Quality of Care (Qoc) Scores in Paediatric Hospital Wards During Winter Periods.

Standaert B, Li X, Strens D, Schecroun N, Raes M.

Value Health. 2015 Nov;18(7):A596-7. doi: 10.1016/j.jval.2015.09.1552. Epub 2015 Oct 20. No abstract available.

PMID:
26533351
5.

Economic Evaluation Of The Rotavirus Vaccination Among Children Under 5 Years Of Age In Switzerland.

Li X, Standaert B.

Value Health. 2015 Nov;18(7):A585. doi: 10.1016/j.jval.2015.09.1962. Epub 2015 Oct 20. No abstract available.

PMID:
26533289
6.

Epidemiological Data Used In Rotavirus Vaccination Cost-Effectiveness Analysis In Europe: A Literature Review Update.

Li X, Theodorou E, Standaert B.

Value Health. 2015 Nov;18(7):A579. doi: 10.1016/j.jval.2015.09.1929. Epub 2015 Oct 20. No abstract available.

PMID:
26533256
7.

Cost of Paediatric Vaccine Administration in the United Kingdom (UK): a Time and Motion (T&M) Study.

Mokiou S, de Cock E, Standaert B.

Value Health. 2015 Nov;18(7):A339. doi: 10.1016/j.jval.2015.09.135. Epub 2015 Oct 20. No abstract available.

PMID:
26531919
8.

Cost effectiveness evaluation of a rotavirus vaccination program in Argentina.

Martí SG, Alcaraz A, Valanzasca P, McMullen M, Standaert B, Garay U, Lepetic A, Gomez J.

Vaccine. 2015 Oct 13;33(42):5684-90. doi: 10.1016/j.vaccine.2015.08.026. Epub 2015 Aug 21.

PMID:
26303875
9.

Dissecting the indirect effects caused by vaccines into the basic elements.

Scarbrough Lefebvre CD, Terlinden A, Standaert B.

Hum Vaccin Immunother. 2015;11(9):2142-57. doi: 10.1080/21645515.2015.1052196. Epub 2015 Jul 17. Review.

10.
11.

Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: An evaluation study in Belgium.

Standaert B, Alwan A, Strens D, Raes M, Postma MJ.

Hum Vaccin Immunother. 2015;11(9):2266-73. doi: 10.1080/21645515.2015.1029212.

12.

Public health impact of accelerated immunization against rotavirus infection among children aged less than 6 months in the United States.

Weycker D, Atwood MA, Standaert B, Krishnarajah G.

Hum Vaccin Immunother. 2014;10(7):2032-8. doi: 10.4161/hv.28689.

13.

Development of a Survey to Quantify Parents' Priorities for Vaccinating Children Against Rotavirus.

Hauber AB, Standaert B, Poulos C.

Value Health. 2014 Nov;17(7):A681. doi: 10.1016/j.jval.2014.08.2541. Epub 2014 Oct 26. No abstract available.

14.

Allocating Vaccine Funds for Pneumococcal Vaccination of Infants and Older Adults: A Method for Strategic Evaluation in the Netherlands.

Delgleize E, Standaert B.

Value Health. 2014 Nov;17(7):A676. doi: 10.1016/j.jval.2014.08.2510. Epub 2014 Oct 26. No abstract available.

15.

How Do Decision Makers in Europe Value Other Economic Evaluation Tools Than Cost-Effectiveness Analysis for Vaccines?

Höhne JM, Demarteau N, Saka Ö, Standaert B, Kleintjens J.

Value Health. 2014 Nov;17(7):A675-6. doi: 10.1016/j.jval.2014.08.2509. Epub 2014 Oct 26. No abstract available.

16.

Workflow Mapping for Paediatric Vaccination Process in the United Kingdom (Uk): A Precursor of A Time and Motion (T&M) Study.

Mokiou S, De CE, Standaert B.

Value Health. 2014 Nov;17(7):A582. doi: 10.1016/j.jval.2014.08.1974. Epub 2014 Oct 26. No abstract available.

17.

Health Economic Model On the Costs and Effects of Rotavirus Vaccination in Romania.

Preda AL, Moise M, Standaert B.

Value Health. 2014 Nov;17(7):A509. doi: 10.1016/j.jval.2014.08.1559. Epub 2014 Oct 26. No abstract available.

18.

Measuring and Observing Positive And Negative Externalities Caused By Vaccines: Do We Have The Right Assessment Approach Available?

Lefebvre C, Terlinden A, Standaert B.

Value Health. 2014 Nov;17(7):A450. doi: 10.1016/j.jval.2014.08.1215. Epub 2014 Oct 26. No abstract available.

19.

Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn?

Standaert B, Ethgen O, Emerson R, Postma M, Mauskopf J.

Adv Ther. 2014 Oct;31(10):1095-108. doi: 10.1007/s12325-014-0160-6. Epub 2014 Oct 21.

20.

Reassessing the value of vaccines.

Bärnighausen T, Berkley S, Bhutta ZA, Bishai DM, Black MM, Bloom DE, Constenla D, Driessen J, Edmunds J, Evans D, Griffiths U, Hansen P, Hashmani FN, Hutubessy R, Jamison DT, Jha P, Jit M, Johnson H, Laxminarayan R, Lee BY, Mhatre S, Mills A, Nordström A, Ozawa S, Prosser L, Silver K, Benn CS, Standaert B, Walker D.

Lancet Glob Health. 2014 May;2(5):e251-2. doi: 10.1016/S2214-109X(13)70170-0. Epub 2014 Apr 23. No abstract available. Erratum in: Lancet Glob Health. 2014 Jun;2(6):e322.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk